{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:00:00Z","timestamp":1794852000419,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cystic fibrosis (CF) is a genetic disease characterized by CF transmembrane regulator (CFTR) dysfunction. With over 2000 CFTR variants identified, in addition to known patient to patient variability, there is a need for personalized treatment. The discovery of CFTR modulators has shown efficacy in certain CF populations, however there are still CF populations without valid therapeutic options. With evidence suggesting that single drug therapeutics are insufficient for optimal management of CF disease, there has been an increased pursuit of combinatorial therapies. Our aim was to test cyclic AMP (cAMP) modulation, through ATP Binding Cassette Transporter C4 (ABCC4) and phosphodiesterase-4 (PDE-4) inhibition, as a potential add-on therapeutic to a clinically approved CFTR modulator, VX-770, as a method for increasing CFTR activity. Human airway epithelial cells (Calu-3) were used to test the efficacy of cAMP modulation by ABCC4 and PDE-4 inhibition through a series of concentration\u2013response studies. Our results showed that cAMP modulation, in combination with VX-770, led to an increase in CFTR activity via an increase in sensitivity when compared to treatment of VX-770 alone. Our study suggests that cAMP modulation has potential to be pursued as an add-on therapy for the optimal management of CF disease.<\/jats:p>","DOI":"10.1038\/s41598-020-79555-w","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T06:26:43Z","timestamp":1610519203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Modulation of cAMP metabolism for CFTR potentiation in human airway epithelial cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Jenny P.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Tiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"79555_CR1","doi-asserted-by":"crossref","unstructured":"Riordan, J. R. et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science (80-. ). 245, 1066\u20131073 (1989).","DOI":"10.1126\/science.2475911"},{"key":"79555_CR2","doi-asserted-by":"crossref","unstructured":"Anderson, M. P. et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science (80-. ). 253, 202\u2013205 (1991).","DOI":"10.1126\/science.1712984"},{"key":"79555_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/0092-8674(92)90155-6","volume":"68","author":"CE Bear","year":"1992","unstructured":"Bear, C. E. et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68, 809\u2013818 (1992).","journal-title":"Cell"},{"key":"79555_CR4","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1172\/JCI115696","volume":"89","author":"JJ Smith","year":"1992","unstructured":"Smith, J. J. & Welsh, M. J. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia. J. Clin. Invest. 89, 1148\u20131153 (1992).","journal-title":"J. Clin. Invest."},{"key":"79555_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","volume":"74","author":"V Saint-Criq","year":"2017","unstructured":"Saint-Criq, V. & Gray, M. A. Role of CFTR in epithelial physiology. Cell. Mol. Life Sci. 74, 93\u2013115 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"79555_CR6","doi-asserted-by":"publisher","first-page":"8119","DOI":"10.1073\/pnas.131087598","volume":"98","author":"S Jayaraman","year":"2001","unstructured":"Jayaraman, S., Joo, N. S., Reitz, B., Wine, J. J. & Verkman, A. S. Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity. Proc. Natl. Acad. Sci. U. S. A. 98, 8119\u20138123 (2001).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79555_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1172\/JCI83922","volume":"126","author":"XX Tang","year":"2016","unstructured":"Tang, X. X. et al. Acidic pH increases airway surface liquid viscosity in cystic fibrosis. J. Clin. Invest. 126, 879\u2013891 (2016).","journal-title":"J. Clin. Invest."},{"key":"79555_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature11130","volume":"487","author":"AA Pezzulo","year":"2012","unstructured":"Pezzulo, A. A. et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487, 109\u2013113 (2012).","journal-title":"Nature"},{"key":"79555_CR9","doi-asserted-by":"publisher","first-page":"18703","DOI":"10.1073\/pnas.1422091112","volume":"111","author":"MHA Alaiwa","year":"2014","unstructured":"Alaiwa, M. H. A. et al. pH modulates the activity and synergism of the airway surface liquid antimicrobials \u03b2-defensin-3 and LL-37. Proc. Natl. Acad. Sci. U. S. A. 111, 18703\u201318708 (2014).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79555_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","volume":"73","author":"MJ Welsh","year":"1993","unstructured":"Welsh, M. J. & Smith, A. E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73, 1251\u20131254 (1993).","journal-title":"Cell"},{"key":"79555_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","volume":"29","author":"J Zielenski","year":"1995","unstructured":"Zielenski, J. & Tsui, L.-C. Cystic Fibrosis: Genotypic and Phenotypic Variations. Annu. Rev. Genet. 29, 777\u2013807 (1995).","journal-title":"Annu. Rev. Genet."},{"key":"79555_CR12","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","volume":"352","author":"SM Rowe","year":"2005","unstructured":"Rowe, S. M., Miller, S. & Sorscher, E. J. Cystic fibrosis. N. Engl. J. Med. 352, 1992\u20132001 (2005).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit, G. et al. From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations. Mol. Biol. Cell 27, 424\u2013433 (2016).","journal-title":"Mol. Biol. Cell"},{"key":"79555_CR14","doi-asserted-by":"crossref","unstructured":"Ahmadi, S. et al. Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia. npj Genomic Med. 2, 1\u201310 (2017).","DOI":"10.1038\/s41525-017-0015-6"},{"key":"79555_CR15","unstructured":"KALYDECO (ivacaftor) Package Insert. (Vertex Pharmaceuticals Incorporated, Boston, 2019)."},{"key":"79555_CR16","unstructured":"ORKAMBI (lumacaftor\/ivacaftor) Package Insert. (Vertex Pharmaceuticals Incorporated, Boston, 2019)."},{"key":"79555_CR17","unstructured":"SYMDEKO (tezacaftor\/ivacaftor) Package Insert. (Vertex Pharmaceuticals Incorporated, Boston, 2019)."},{"key":"79555_CR18","unstructured":"TRIKAFTA (elexacaftor, tezacaftor and ivacaftor) Package Insert. (Vertex Pharmaceuticals Incorporated, Boston, 2020)."},{"key":"79555_CR19","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. U. S. A. 106, 18825\u201318830 (2009).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79555_CR20","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","volume":"363","author":"FJ Accurso","year":"2010","unstructured":"Accurso, F. J. et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363, 1991\u20132003 (2010).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR21","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663\u20131672 (2011).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR22","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Van Goor","year":"2011","unstructured":"Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U. S. A. 108, 18843\u201318848 (2011).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79555_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","volume":"2","author":"MP Boyle","year":"2014","unstructured":"Boyle, M. P. et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet. Respir. Med. 2, 527\u2013538 (2014).","journal-title":"Lancet. Respir. Med."},{"key":"79555_CR24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright, C. E., Elborn, J. S. & Ramsey, B. W. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 373, 1783\u20131784 (2015).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR25","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","volume":"377","author":"JL Taylor-Cousar","year":"2017","unstructured":"Taylor-Cousar, J. L. et al. Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N. Engl. J. Med. 377, 2013\u20132023 (2017).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR26","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","volume":"377","author":"SM Rowe","year":"2017","unstructured":"Rowe, S. M. et al. Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis. N. Engl. J. Med. 377, 2024\u20132035 (2017).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR27","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612\u20131620 (2018).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR29","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","volume":"379","author":"JC Davies","year":"2018","unstructured":"Davies, J. C. et al. VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1599\u20131611 (2018).","journal-title":"N. Engl. J. Med."},{"key":"79555_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jcf.2019.04.014","volume":"18","author":"SC Bell","year":"2019","unstructured":"Bell, S. C. et al. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. J. Cyst. Fibros. 18, 700\u2013707 (2019).","journal-title":"J. Cyst. Fibros."},{"key":"79555_CR31","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0092-8674(91)90446-6","volume":"66","author":"SH Cheng","year":"1991","unstructured":"Cheng, S. H. et al. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66, 1027\u20131036 (1991).","journal-title":"Cell"},{"key":"79555_CR32","doi-asserted-by":"publisher","first-page":"12742","DOI":"10.1016\/S0021-9258(18)42339-3","volume":"267","author":"MR Picciotto","year":"1992","unstructured":"Picciotto, M. R., Cohn, J. A., Bertuzzi, G., Greengard, P. & Nairn, A. C. Phosphorylation of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 267, 12742\u201312752 (1992).","journal-title":"J. Biol. Chem."},{"key":"79555_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/38514","volume":"389","author":"MC Winter","year":"1997","unstructured":"Winter, M. C. & Welsh, M. J. Stimulation of CFTR activity by its phosphorylated R domain. Nature 389, 294\u2013296 (1997).","journal-title":"Nature"},{"key":"79555_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cell.2007.09.037","volume":"131","author":"C Li","year":"2007","unstructured":"Li, C. et al. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131, 940\u2013951 (2007).","journal-title":"Cell"},{"key":"79555_CR35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1165\/rcmb.2013-0156OC","volume":"49","author":"GE Conner","year":"2013","unstructured":"Conner, G. E., Ivonnet, P., Gelin, M., Whitney, P. & Salathe, M. HO Stimulates CFTR through an autocrine prostaglandin pathway using MRP4. Am. J. Respir. Cell Mol. Biol. 49, 672\u2013679 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"79555_CR36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1165\/rcmb.2002-0247OC","volume":"29","author":"BR Cobb","year":"2003","unstructured":"Cobb, B. R., Fan, L., Kovacs, T. E., Sorscher, E. J. & Clancy, J. P. Adenosine receptors and phosphodiesterase inhibitors stimulate Cl - secretion in Calu-3 cells. Am. J. Respir. Cell Mol. Biol. 29, 410\u2013418 (2003).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"79555_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1096\/fj.13-240861","volume":"28","author":"E Blanchard","year":"2014","unstructured":"Blanchard, E. et al. Anchored PDE4 regulates chloride conductance in wild-type and \u0394f508-CFTR human airway epithelia. FASEB J. 28, 791\u2013801 (2014).","journal-title":"FASEB J."},{"key":"79555_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1165\/rcmb.2013-0228OC","volume":"50","author":"JA Lambert","year":"2014","unstructured":"Lambert, J. A. et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am. J. Respir. Cell Mol. Biol. 50, 549\u2013558 (2014).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"79555_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1073\/pnas.0135434100","volume":"100","author":"AP Naren","year":"2003","unstructured":"Naren, A. P. et al. A macromolecular complex of \u03b22 adrenergic receptor, CFTR, and ezrin\/radixin\/moesin-binding phosphoprotein 50 is regulated by PKA. Proc. Natl. Acad. Sci. U. S. A. 100, 342\u2013346 (2003).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79555_CR40","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/12487","volume":"5","author":"JD Schuetz","year":"1999","unstructured":"Schuetz, J. D. et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5, 1048\u20131051 (1999).","journal-title":"Nat. Med."},{"key":"79555_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/mi.2015.104","volume":"9","author":"MJ Gold","year":"2016","unstructured":"Gold, M. J. et al. Mucosal production of uric acid by airway epithelial cells contributes to particulate matter-induced allergic sensitization. Mucosal Immunol. 9, 809\u2013820 (2016).","journal-title":"Mucosal Immunol."},{"key":"79555_CR42","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jaci.2017.10.011","volume":"141","author":"RD Huff","year":"2018","unstructured":"Huff, R. D. et al. Inhibition of ABCC4 potentiates combination beta agonist and glucocorticoid responses in human airway epithelial cells. J. Allergy Clin. Immunol. 141, 1127-1130.e5 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"79555_CR43","doi-asserted-by":"crossref","unstructured":"Turner, M. J. et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am. J. Physiol. - Lung Cell. Mol. Physiol. 310, L59\u2013L70 (2016).","DOI":"10.1152\/ajplung.00324.2015"},{"key":"79555_CR44","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/144.3_pt_1.617","author":"JC Kips","year":"1991","unstructured":"Kips, J. C. et al. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am. Rev. Respir. Dis. https:\/\/doi.org\/10.1164\/ajrccm\/144.3_pt_1.617 (1991).","journal-title":"Am. Rev. Respir. Dis."},{"key":"79555_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bcp.2014.05.023","volume":"91","author":"L Cheung","year":"2014","unstructured":"Cheung, L. et al. High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochem. Pharmacol. 91, 97\u2013108 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"79555_CR46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","volume":"374","author":"PM Calverley","year":"2009","unstructured":"Calverley, P. M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 374, 685\u2013694 (2009).","journal-title":"Lancet"},{"key":"79555_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","volume":"374","author":"LM Fabbri","year":"2009","unstructured":"Fabbri, L. M. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374, 695\u2013703 (2009).","journal-title":"Lancet"},{"key":"79555_CR48","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","volume":"385","author":"FJ Martinez","year":"2015","unstructured":"Martinez, F. J. et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. Lancet 385, 857\u2013866 (2015).","journal-title":"Lancet"},{"key":"79555_CR49","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1378\/chest.14-1676","volume":"147","author":"GJ Criner","year":"2015","unstructured":"Criner, G. J. et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 147, 894\u2013942 (2015).","journal-title":"Chest"},{"key":"79555_CR50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0028-3908(83)90239-3","volume":"22","author":"H Wachtel","year":"1983","unstructured":"Wachtel, H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3\u2032,5\u2032-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22, 267\u2013272 (1983).","journal-title":"Neuropharmacology"},{"key":"79555_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1527-3458.2001.tb00206.x","volume":"7","author":"J Zhu","year":"2001","unstructured":"Zhu, J., Mix, E. & Winblad, B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev. 7, 387\u2013398 (2001).","journal-title":"CNS Drug Rev."},{"key":"79555_CR52","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tips.2004.01.003","volume":"25","author":"JM O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell, J. M. & Zhang, H. T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 25, 158\u2013163 (2004).","journal-title":"Trends Pharmacol. Sci."},{"key":"79555_CR53","doi-asserted-by":"crossref","unstructured":"Shen, B. Q., Finkbeiner, W. E., Wine, J. J., Mrsny, R. J. & Widdicombe, J. H. Calu-3: A human airway epithelial cell line that shows cAMP-dependent Cl- secretion. Am. J. Physiol.-Lung Cell. Mol. Physiol. 266 (1994).","DOI":"10.1152\/ajplung.1994.266.5.L493"},{"key":"79555_CR54","doi-asserted-by":"crossref","unstructured":"Haws, C., Finkbeiner, W. E., Widdicombe, J. H. & Wine, J. J. CFTR in Calu-3 human airway cells: Channel properties and role in cAMP-activated Cl-conductance. Am. J. Physiol. Lung Cell. Mol. Physiol. 266 (1994).","DOI":"10.1152\/ajplung.1994.266.5.L502"},{"key":"79555_CR55","doi-asserted-by":"publisher","first-page":"22578","DOI":"10.1074\/jbc.M401522200","volume":"279","author":"K Varga","year":"2004","unstructured":"Varga, K. et al. Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines. J. Biol. Chem. 279, 22578\u201322584 (2004).","journal-title":"J. Biol. Chem."},{"key":"79555_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/10611860290007504","volume":"10","author":"NR Mathias","year":"2002","unstructured":"Mathias, N. R. et al. Permeability characteristics of Calu-3 human bronchial epithelial cells: In vitro-in vitro correlation to predict lung absorption in rats. J. Drug Target. 10, 31\u201340 (2002).","journal-title":"J. Drug Target."},{"key":"79555_CR57","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s11095-006-0255-0","volume":"23","author":"CI Grainger","year":"2006","unstructured":"Grainger, C. I., Greenwell, L. L., Lockley, D. J., Martin, G. P. & Forbes, B. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm. Res. 23, 1482\u20131490 (2006).","journal-title":"Pharm. Res."},{"key":"79555_CR58","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3109\/03639041003695113","volume":"36","author":"M Haghi","year":"2010","unstructured":"Haghi, M. et al. Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev. Ind. Pharm. 36, 1207\u20131214 (2010).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"79555_CR59","first-page":"109","volume":"22","author":"I Litosch","year":"1982","unstructured":"Litosch, I., Hudson, T. H., Mills, I. & Fain, J. N. Forskolin an an activator of cyclic AMP accumulation and lipolysis in rat adipocytes. Mol. Pharmacol. 22, 109\u2013115 (1982).","journal-title":"Mol. Pharmacol."},{"key":"79555_CR60","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1139\/y83-179","volume":"61","author":"RVK Vegesna","year":"1983","unstructured":"Vegesna, R. V. K. & Diamond, J. Comparison of the effects of forskolin and isoproterenol on cyclic AMP levels and tension in bovine coronary artery. Can. J. Physiol. Pharmacol. 61, 1202\u20131205 (1983).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"79555_CR61","doi-asserted-by":"publisher","first-page":"10233","DOI":"10.1016\/S0021-9258(17)44447-4","volume":"258","author":"ILO Buxton","year":"1983","unstructured":"Buxton, I. L. O. & Brunton, L. L. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J. Biol. Chem. 258, 10233\u201310239 (1983).","journal-title":"J. Biol. Chem."},{"key":"79555_CR62","first-page":"1260","volume":"261","author":"H-L Zhou","year":"1992","unstructured":"Zhou, H.-L., Newsholme, S. J. & Torphy, T. J. Agonist-related differences in the relationship between cAMP content and protein kinase activity in canine trachealis. J. Pharmacol. Exp. Ther. 261, 1260\u20131267 (1992).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"79555_CR63","doi-asserted-by":"crossref","unstructured":"Reenstra, W. W., Yurko-Mauro, K., Dam, A., Raman, S. & Shorten, S. CFTR chloride channel activation by genistein: The role of serine\/threonine protein phosphatases. Am. J. Physiol. Cell Physiol. 271 (1996).","DOI":"10.1152\/ajpcell.1996.271.2.C650"},{"key":"79555_CR64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1165\/rcmb.2008-0091TR","volume":"39","author":"CH Serezani","year":"2008","unstructured":"Serezani, C. H., Ballinger, M. N., Aronoff, D. M. & Peters-Golden, M. Cyclic AMP: Master regulator of innate immune cell function. Am. J. Respir. Cell Mol. Biol. 39, 127\u2013132 (2008).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"79555_CR65","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1073\/pnas.78.6.3363","volume":"78","author":"KB Seamon","year":"1981","unstructured":"Seamon, K. B., Padgett, W. & Daly, J. W. Forskolin: Unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. U. S. A. 78, 3363\u20133367 (1981).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79555_CR66","doi-asserted-by":"publisher","first-page":"14120","DOI":"10.1073\/pnas.241318498","volume":"98","author":"P Huang","year":"2001","unstructured":"Huang, P. et al. Compartmentalized autocrine signaling to cystic fibrosis transmembrane conductance regulator at the apical membrane of airway epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 98, 14120\u201314125 (2001).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"79555_CR67","first-page":"381","volume":"49","author":"I Feoktistov","year":"1997","unstructured":"Feoktistov, I. & Biaggioni, I. Adenosine A2B receptors. Pharmacol. Rev. 49, 381\u2013402 (1997).","journal-title":"Pharmacol. Rev."},{"key":"79555_CR68","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.bi.56.070187.003151","volume":"56","author":"AG Gilman","year":"1987","unstructured":"Gilman, A. G. G proteins: Transducers of receptor-generated signals. Annu. Rev. Biochem. 56, 615\u2013649 (1987).","journal-title":"Annu. Rev. Biochem."},{"key":"79555_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-pharmtox-010611-134609","volume":"53","author":"S Cheepala","year":"2013","unstructured":"Cheepala, S. et al. Cyclic nucleotide compartmentalization: Contributions of phosphodiesterases and ATP-binding cassette transporters. Annu. Rev. Pharmacol. Toxicol. 53, 231\u2013253 (2013).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"79555_CR70","doi-asserted-by":"publisher","first-page":"9027","DOI":"10.1158\/0008-5472.CAN-04-3703","volume":"64","author":"RD Ramirez","year":"2004","unstructured":"Ramirez, R. D. et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64, 9027\u20139034 (2004).","journal-title":"Cancer Res."},{"key":"79555_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1165\/rcmb.2014-0158OC","volume":"52","author":"JA Hirota","year":"2015","unstructured":"Hirota, J. A. et al. The nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome\/IL-1 receptor I axis mediates innate, but not adaptive, immune responses after exposure to particulate matter under 10 \u03bcm. Am. J. Respir. Cell Mol. Biol. 52, 96\u2013105 (2015).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"79555_CR72","doi-asserted-by":"crossref","unstructured":"Huff, R. D. et al. Regulation of xanthine dehydrogensase gene expression and uric acid production in human airway epithelial cells. PLoS One 12 (2017).","DOI":"10.1371\/journal.pone.0184260"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79555-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79555-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79555-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T20:50:12Z","timestamp":1670014212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79555-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["79555"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-79555-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.11.294223","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"904"}}